基于肠肾轴理论探析肾炎消白方治疗IgA肾病作用机制
Study on the Mechanism of Shenyan Xiaobai Decoction in Treating IgA Nephropathy Based on the Gut-Kidney Axis Theory
DOI: 10.12677/tcm.2026.1510545, PDF,   
作者: 程龙朱, 李莲花*：黑龙江省中医药科学院，黑龙江 哈尔滨
关键词: 肠肾轴；肾炎消白方；IgA肾病；Gut-Kidney Axis； Shenyan Xiaobai Decoction； IgA Nephropathy
摘要: IgA肾病作为一种常见的原发性肾小球疾病，其具体发病机制目前仍未完全阐明。近年来，肠–肾轴理论指出，肠道黏膜屏障的功能状态及其结构完整性，在IgA肾病的起始与进展中发挥着重要作用。肾炎消白方在多种系统性疾病，尤其是与黏膜相关的病变中显示出良好疗效，且已有大量研究证实其对肠道黏膜具有修复效应。本文基于对IgA肾病中肠–肾轴相关病理机制的梳理，结合肾炎消白方的药理作用特点，进一步探讨该方用于IgA肾病治疗的潜在合理性，以期为经典方剂的现代临床拓展提供理论依据。
Abstract: IgA nephropathy is a common primary glomerular disease, and its specific pathogenesis is still not fully elucidated. In recent years, the theory of gut-kidney axis has pointed out that the functional status and structural integrity of the intestinal mucosal barrier play an important role in the initiation and progression of IgA nephropathy. Shenyan Xiaobai Decoction has shown good efficacy in a variety of systemic diseases, especially mucosal-related lesions, and a large number of studies have confirmed its repair effect on intestinal mucosa. Based on the review of the pathological mechanism of the gut-kidney axis in IgA nephropathy, combined with the pharmacological characteristics of Shenyan Xiaobai Decoction, this paper further explores the potential rationality of this prescription for the treatment of IgA nephropathy, in order to provide a theoretical basis for the modern clinical expansion of classical prescriptions.
文章引用：程龙朱, 李莲花. 基于肠肾轴理论探析肾炎消白方治疗IgA肾病作用机制[J]. 中医学, 2026, 15(10): 206-212. https://doi.org/10.12677/tcm.2026.1510545

参考文献

[1] Schena, F.P. and Nistor, I. (2018) Epidemiology of IgA Nephropathy: A Global Perspective. Seminars in Nephrology, 38, 435-442.
https://doi.org/10.1016/j.semnephrol.2018.05.013
[2] Monteiro, R.C., Rafeh, D. and Gleeson, P.J. (2022) Is There a Role for Gut Microbiome Dysbiosis in IgA Nephropathy? Microorganisms, 10, Article No. 683.
https://doi.org/10.3390/microorganisms10040683
[3] Gutiérrez, E., Carvaca-Fontán, F., Luzardo, L., Morales, E., Alonso, M. and Praga, M. (2020) A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges. Nephron, 144, 555-571.
https://doi.org/10.1159/000509997
[4] 刘婕, 赵晋, 余紫娴, 等. “肠-肾轴”与IgA肾病: 机制与靶向干预策略[J/OL]. 空军军医大学学报, 1-19.
https://link.cnki.net/urlid/61.1526.R.20260227.1540.008, 2026-09-02.
[5] Chen, Y., Chen, D., Chen, L., Liu, J., Vaziri, N.D., Guo, Y., et al. (2019) Microbiome-Metabolome Reveals the Contribution of Gut-Kidney Axis on Kidney Disease. Journal of Translational Medicine, 17, Article No. 5.
https://doi.org/10.1186/s12967-018-1756-4
[6] Barratt, J., Rovin, B.H., Cattran, D., Floege, J., Lafayette, R., Tesar, V., et al. (2020) Why Target the Gut to Treat IgA Nephropathy? Kidney International Reports, 5, 1620-1624.
https://doi.org/10.1016/j.ekir.2020.08.009
[7] 赵雪千, 王雯瑾, 张楠辉, 等. IgA肾病患者补体血清水平及其系膜沉积强度与肾病理损伤程度的相关性[J]. 陕西医学杂志, 2025, 54(4): 555-559.
[8] Monteiro, R.C. and Berthelot, L. (2021) Role of Gut-Kidney Axis in Renal Diseases and IgA Nephropathy. Current Opinion in Gastroenterology, 37, 565-571.
https://doi.org/10.1097/mog.0000000000000789
[9] Ahlawat, S., Asha, and Sharma, K.K. (2021) Gut-Organ Axis: A Microbial Outreach and Networking. Letters in Applied Microbiology, 72, 636-668.
https://doi.org/10.1111/lam.13333
[10] Coppo, R. (2015) The Intestine-Renal Connection in IgA Nephropathy. Nephrology Dialysis Transplantation, 30, 360-366.
https://doi.org/10.1093/ndt/gfu343
[11] 郁洁, 周楠, 沈颖. IgA肾病肠道黏膜免疫致病机制的研究进展[J]. 北京医学, 2020, 42(11): 1141-1144.
[12] 何永, 马君, 何敬华. 黄帝内经素问[M]. 第2版. 北京: 中国中医药出版社, 2022.
[13] 唐宗海, 魏武英, 李佺. 血证论[M]. 北京: 人民卫生出版社, 2017.
[14] 郑娱, 杨婧, 王琛. “消白方颗粒”联合硫酸羟氯喹治疗IgA肾病蛋白尿33例临床研究[J]. 江苏中医药, 2021, 53(11): 35-39.
[15] 苑通, 刘子洋, 张佩青. 张佩青教授运用自拟肾炎消白方治疗蛋白尿的经验举隅[J]. 中国中西医结合肾病杂志, 2016, 17(11): 950-951.
[16] 沈世忠, 杨忠民, 蔡佳盈, 等. 黄芪注射液对IgA肾病患者免疫球蛋白分子异常糖基化及Cosmc基因表达的影响[J]. 中国老年学杂志, 2017, 37(11): 2788-2789.
[17] 闫智杰, 贾宝辉, 陈军喜, 等. 黄芪多糖对脓毒症大鼠核因子-κB和Th1/Th2型细胞因子及CD4+/CD8+比值的影响[J]. 江西医药, 2011, 46(8): 703-705.
[18] Su, M., Tang, T., Tang, W., Long, Y., Wang, L. and Liu, M. (2023) Astragalus Improves Intestinal Barrier Function and Immunity by Acting on Intestinal Microbiota to Treat T2DM: A Research Review. Frontiers in Immunology, 14, Article ID: 1243834.
https://doi.org/10.3389/fimmu.2023.1243834
[19] 史宝忠, 胡建燃, 李平, 等. 党参多糖对Ana-1巨噬细胞和小鼠的免疫调节作用[J]. 生物技术通报, 2019, 35(6): 114-118.
[20] 唐梦佳, 刘庆庆, 刘延鑫, 等. 党参多糖的生物活性及产品开发研究进展[J]. 食品工业科技, 2022, 43(20): 464-470.
[21] Alamgeer, Niazi, S.G., Uttra, A.M., Qaiser, M.N. and Ahsan, H. (2017) Appraisal of Anti-Arthritic and Nephroprotective Potential of Cuscuta reflexa. Pharmaceutical Biology, 55, 792-798.
https://doi.org/10.1080/13880209.2017.1280513
[22] Liu, X., Xu, H., Zang, Y., Liu, W. and Sun, X. (2022) Radix Rehmannia glutinosa Inhibits the Development of Renal Fibrosis by Regulating miR-122-5p/PKM Axis. American Journal of Translational Research, 14, 103-119.
[23] Liu, Z.H., Xu, Q., Wang, Y., Gao, H., Min, Y., Jiang, X., et al. (2024) Catalpol from Rehmannia glutinosa Targets Nrf2/NF-κB Signaling Pathway to Improve Renal Anemia and Fibrosis. The American Journal of Chinese Medicine, 52, 1451-1485.
https://doi.org/10.1142/s0192415x24500575
[24] Xie, W., Huang, Y., Chen, H. and Zhou, X. (2021) Study on the Efficacy and Mechanism of Lycium barbarum Polysaccharide against Lead-Induced Renal Injury in Mice. Nutrients, 13, Article No. 2945.
https://doi.org/10.3390/nu13092945
[25] Qu, F., Bian, Y., Yu, Y., et al. (2020) Lycium barbarum Polysaccharide Inhibits Inflammatory Response in Rats with Diabetic Nephropathy via TLR4/MyD88 Pathway. Progress in Anatomical Sciences, 26, 378-382.
[26] Zhu, W., Zhou, S., Liu, J., McLean, R.J.C. and Chu, W. (2020) Prebiotic, Immuno-Stimulating and Gut Microbiota-Modulating Effects of Lycium barbarum Polysaccharide. Biomedicine & Pharmacotherapy, 121, Article ID: 109591.
https://doi.org/10.1016/j.biopha.2019.109591
[27] 张明发, 沈雅琴. 女贞子抗炎、抗肿瘤和免疫调节作用的研究进展[J]. 现代药物与临床, 2012, 27(5): 536-542.
[28] Shi, Y., Tian, C., Yu, X., Fang, Y., Zhao, X., Zhang, X., et al. (2020) Protective Effects of Smilax glabra Roxb. against Lead-Induced Renal Oxidative Stress, Inflammation and Apoptosis in Weaning Rats and HEK-293 Cells. Frontiers in Pharmacology, 11, Article ID: 556248.
https://doi.org/10.3389/fphar.2020.556248
[29] 廖兰, 林思童, 梁骏峰, 等. 药食同源薏苡仁药理活性成分研究进展[J]. 食品科学, 2025, 46(10): 358-367.
[30] 李帅印, 杨萍, 葸慧荣, 等. 白茅根化学成分与药理作用研究进展及其质量标志物预测[J]. 中国新药杂志, 2025, 34(13): 1406-1416.